Mission
Invivyd is a biopharmaceutical company on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2.
By pairing state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering techniques, we are committed to developing a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.
Leadership team
Invivyd’s leadership team is composed of seasoned executives with decades of combined experience developing and commercializing novel medicines for infectious diseases. Our leadership team includes individuals with extensive experience delivering vaccines that have helped protect people around the globe from serious viral threats, as well as leaders who have helped pioneer the development of monoclonal antibodies for use in the prevention and treatment of COVID-19.
Robert Allen, Ph.D.
Chief Scientific Officer
Jill Andersen, J.D.
Chief Legal Officer & Corporate Secretary
William Duke, M.B.A.
Chief Financial Officer
Julie Green, M.B.A.
Chief Human Resources Officer
Timothy Lee
Chief Commercial Officer
Stacy Price, M.S.
Chief Technology & Manufacturing Officer
Mark Wingertzahn, Ph.D.
Senior Vice President of Clinical Development and Medical Affairs
Board of directors
Tamsin Berry
Director
Sara Cotter
Director
Marc Elia
Chairperson of the Board
Srishti Gupta, M.D.
Director
Christine Lindenboom
Director
Terry McGuire
Director
Kevin F. McLaughlin
Director
Partnerships
To achieve our mission, we have entered into a number of strategic partnerships and continue to evaluate potentially synergistic partnering opportunities, such as commercial partnerships that would help ensure that our portfolio of product candidates are available to as many vulnerable people as possible. In addition, we are exploring opportunities to partner with universities, academic medical centers, or other biopharmaceutical companies that have interest in leveraging our unique platform-based approach for asset and technology research and development.
Please contact us to explore partnering opportunities
